Maximizing the Impact of Respiratory Analytics and Insights Teams

Industries Profiled:
Pharmaceutical; Biotech; Research; Consulting; Diagnostic; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
AstraZeneca; Biotest AG; Boehringer Ingelheim; Grünenthal; Klosterfrau Healthcare Group; Lonza Inc.; MEDiSTRAVA; Qiagen; Sanofi; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 11 Analytics & Insights leaders across 10 top biopharma companies with a focus on the respiratory segment. This report includes segmentation by company size (mid vs. large pharma) and features deep-dive interviews for added qualitative insights. Notably, over 35% of benchmark participants serve at the director-level or above.

Key topics covered in this report include:

• Core responsibilities and clients supported by Respiratory A&I teams
• Strategic practices, critical skill sets, and high-demand expertise areas
• High-value analytics types, methodologies, platforms and outsourcing models
• Streamlining market research through advanced analytics
• Internal branding programs
• Innovation centers of excellence: Usage, staffing, services and alignment
• Common A&I pitfalls, challenges, and lessons
• Innovative pilots, design thinking and patient-centric engagement

• A&I Methodologies Used: Commercial stakeholders are most often supported by respiratory A&I groups, most often with visualization (90%), forecasting (90%), data mining (80%), regression (70%), machine learning (67%) and network & cluster analysis (60%). Less than 1/3 of internal clients (Corporate/brands, HEOR & Medical Affairs) are supported with these analytics. Additionally, high number of respiratory A&I teams do not use pattern matching (80%), simulation (60%), semantic analysis (60%) and predictive analytics (60%) methodologies for any internal stakeholders.

• Outsourcing Levels: More than half of respiratory companies completely insource projects considered “high-value”, which include analyzing market trends, building value propositions, and post-launch product performance. Hybrid approaches are common for most other activities, while complete outsourcing is rare.

• Percentage of time spent by Respiratory Analytics & Insights groups in support of various internal teams
• Percentage of time spent by Analytics & Insights groups in support of various internal teams – Large pharma vs. mid-pharma
• Voices from the field: Building holistic view for improving business results
• Core responsibilities of Respiratory Analytics & Insights groups
• Core responsibilities of Respiratory Analytics & Insights groups – Large pharma vs. mid-pharma

• Strategic practices used by Respiratory Analytics & Insights groups to provide greater value to stakeholders
• Voices from the field: Making consensual and collaborative plans and recommendations to clients
• Effective practices used by Analytics & Insights groups to provide greater value to stakeholders – Large pharma vs. mid-pharma
• Preferred professional experiences and soft skills for Analytics & Insights professionals to have in order to deliver the highest value to internal partners
• Interview narratives around staffing an analytics organization
• Preferred professional experiences and soft skills for Analytics & Insights professionals to have in order to deliver the highest value to internal partners – Large pharma vs. mid-pharma
• Most critical knowledge areas and technical skills for Analytics & Insights team members to have in order to provide maximum value as a strategy partner to internal partners
• Most critical knowledge areas and technical skills for Analytics & Insights team members to have in order to provide maximum value as a strategy partner to internal partners – Large pharma vs. mid-pharma
• Top obstacles to the future success of the Respiratory Analytics & Insights function
• Interview narratives around what can drive the approach to analytics capabilities
• Interview narrative around analytics and different therapeutic areas
• Greatest obstacles to the future success of the Analytics & Insights function – Large pharma vs. mid-pharma
• Common mistake areas for the Analytics & Insights function
• Innovative ways to foster ongoing innovation in providing greater value to stakeholders

• Analytic methodologies used by Respiratory Analytics & Insights groups for different operational purposes
• Analytic methodologies used by Analytics & Insights groups for different operational purposes – Strategic A&I teams vs. total benchmark class
• Interview narrative around determining “Next Best Action” in promotional mix
• Analytic methodologies used by Analytics & Insights groups for different operational purposes – Large pharma vs. mid-pharma
• Interview narrative around predictive analytics in R&D
• Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Total benchmark class
• Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Strategic A&I teams
• Interview narratives around the outputs from new analytics platforms
• Interview narratives around data mining and usage with digitization
• Valuable analytics projects for informing brand, HEOR and other key internal partner teams and driving measurable results in the market – Large pharma vs. mid-pharma
• Interview narrative around characterizing the activities that are enabling to connect the dots, in terms of analytic operations and methodologies performed
• Insource vs. outsource approach for respiratory analytics projects – Total benchmark class
• Insource vs. outsource approach for respiratory analytics projects – Strategic A&I teams
• Interview narrative around benefits of insourcing analytics
• Insource vs. outsource approach for respiratory analytics projects – Large pharma vs. mid-pharma
• Insource vs. outsource approach for specific methodologies and processes
• Insource vs. outsource approach for specific methodologies and processes – Large pharma vs. mid-pharma
• Use of analytics to replace listed market research study types
• Interview narratives around opportunities for more boutique research methodologies
• Interview narratives around approaches that tend to stifle innovation
• Use of analytics to replace listed market research study types – Large pharma vs. mid-pharma
• Most utilized analytics and reporting platforms
• Benchmark peer assessments (pros and cons) of leading analytics platforms
• Interview narrative around an ideal analytics platform in respiratory

• Implementation of an internal branding campaign to change or influence perception of the A&I function
• Important objectives for Analytics & Insights internal branding program – Total benchmark class
• Structural challenges, different data sources, and interview narrative around Analytics & Insights from medical perspective
• Vendor support for internal branding efforts
• Interview narratives around measurement and overall impact of formal branding efforts

• Presence of an innovation CoE to leverage expertise and drive new improvements – Total benchmark class
• Interview narrative around digital solutions by innovation centers of excellence
• Presence of an innovation CoE to leverage expertise and drive new improvements – Large pharma vs. mid-pharma
• Relationship between innovation CoE (or similar department) and Analytics & Insights groups – Total benchmark class and Large pharma vs. mid-pharma
• Number of FTEs working in innovation CoEs or similar departments
• Effective services delivered by innovation CoE (or similar groups) in supporting the overall organization
• Critical professional experiences for staff working in an innovation CoE or similar department

• Employment of a formal design thinking methodology to achieve better performance over time
• Engaging directly with patients to better understand and meet their lifestyle needs relative to the disease state treated by the company’s medicines